SMAD3 and prostate adenocarcinoma: Specifically, ONECUT2 activates SMAD3, which regulates hypoxia signaling through moderating HIF-1α transcriptional binding, causing higher degrees of hypoxia in NEPC compared to prostate adenocarcinomas (40).